Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00188955
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : February 22, 2010
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
University of Manitoba

Brief Summary:

The purpose of this study is to determine whether treatment with sirolimus, in combination with low-dose tacrolimus and prednisone, is effective for the treatment of chronic allograft nephropathy (progressive scarring) in children who have previously received a kidney transplant. This treatment is compared to the standard therapy which uses low-dose tacrolimus, mycophenolate mofetil and prednisons.

This study is a pilot study that will determine whether treatment with sirolimus reduces or improves the rate of scarring seen on kidney biopsy of the transplanted kidney over time, compared to children who continue to be treated with mycophenolate mofetil.

Condition or disease Intervention/treatment Phase
Kidney Transplantation Drug: sirolimus Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 4 Randomized, Controlled Study Comparing Sirolimus and Mycophenolate Mofetil to Prevent or Reverse Progression in Pediatric Renal Transplants With Chronic Allograft Nephropathy
Study Start Date : March 2004
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Sirolimus

Primary Outcome Measures :
  1. histological quantification of interstitial fibrosis at 2 years

Secondary Outcome Measures :
  1. Renal function at 1 and 2 years.
  2. Proteinuria at 2 years.
  3. Freedom from acute rejection and graft loss over the 2 year study period.
  4. Cumulative incidence and prevalence of adverse events and serious adverse events over the 2-year study period.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All male or female patients aged less than 17 years.
  • The patient has undergone a kidney transplant, from a cadaveric or living donor with compatible ABO blood type.
  • The patient is more than 12 months post-transplantation.
  • The allograft demonstrates histological changes consistent with CAN according to the Banff 97 classification schema (minimum of ct1 and ci1 score for tubular atrophy and interstitial fibrosis respectively).

Exclusion Criteria:

  • The patient, or in case the patient is minor, the patient's parent(s) or their legal representative, has been fully informed and will not give informed consent to participate in the study.
  • The allograft demonstrates histological changes at the time of enrollment consistent with acute allograft rejection Grade Ia or worse, according to the Banff 97 classification schema (minimum of t2 and i2 score for tubulitis and interstitial inflammation respectively).
  • The patient is known to be allergic or intolerant to MMF, sirolimus or any of their known metabolites.
  • The patient for who routine protocol kidney biopsy is contraindicated.
  • Patients whose maintenance immunosuppression does not include both tacrolimus and prednisone at the time on study enrollment.
  • Patients previously treated with sirolimus.
  • The patient requires ongoing dosing with a systemic immunosuppressive drug at study entry for any reason other than kidney transplantation.
  • The patient and/or donor is known to be HIV or HCV positive.
  • The patient has significant liver disease, defined as having during the past 28 days continuously elevated ASAT (SGOT) and/or ALAT (SGPT) levels greater than 3 times the upper value of the normal range of the investigational site.
  • The patient has persistent leukopenia (WBC <3.0 x109/L).
  • The patient has persistent thrombocytopenia (<100 x109/L).
  • The patient has pre-existing significant hyperlipidemia (total cholesterol >7.8 mmol/L), not responding to medical therapy.
  • The patient has pre-existing elevated triglycerides, not responding to medical therapy.
  • The patient with malignancy or history of malignancy except for successfully treated Wilm's tumor (2 years) or non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.
  • The patient has significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting or active peptic ulcer.
  • The patient has previously received or is receiving an organ transplant other than kidney.
  • The patient is taking or has been taking an investigational drug in the past 28 days or is currently participating in another clinical intervention trial.
  • Patients with the relapsing, non-diarrheal form of haemolytic-uraemic syndrome.
  • The patient is unlikely to comply with the protocol.
  • The patient has any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may invalidate communication with the investigator
  • Sexually active female patients who are pregnant or lactating or who do not consent to effective birth control.
  • The patient is less than 6 years of age.
  • The patient has significant and persistent EBV activity as measured by PCR amplification from blood samples.
  • The patient has a prior history of post-transplant lymphoproliferative disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00188955

Layout table for location information
Canada, Manitoba
Children's Hospital
Winnipeg, Manitoba, Canada, R3A 1S1
Sponsors and Collaborators
University of Manitoba
Wyeth is now a wholly owned subsidiary of Pfizer
Layout table for investigator information
Principal Investigator: Tom D. Blydt-Hansen, MD University of Manitoba, Manitoba Institute of Child Health

Additional Information:
Layout table for additonal information Identifier: NCT00188955    
Other Study ID Numbers: WINNIPEG-CAN-1
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: February 22, 2010
Last Verified: February 2010
Keywords provided by University of Manitoba:
chronic allograft nephropathy
chronic rejection
interstitial fibrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Urologic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs